03026: Evaluation of the Efficacy of Antioxidant Treatment on Active Kidney Damage and Oxidative Stress
Grant Status: Open
Chronic kidney disease (CKD) is associated with decreased kidney function and accumulation of toxins in the body. The irreversible disease is common in dogs and progressive in nature. Due to its rapid progression, the disease ultimately becomes fatal. Progression is associated with reduced quality of life and longevity. As CKD is incurable, slowing down its progression rate and delaying the onset of clinical signs is the most important therapeutic target. Currently, few interventions are known to effectively attenuate CKD progression, and treatment is mostly aimed at controlling clinical signs and complications; however, when these are present, quality of life has already been affected and the life expectancy is short.
Previous studies demonstrated that animals with an apparently stable CKD have active-ongoing kidney damage, which can be measured using novel biomarkers. This active damage is associated with disease progression. Utilizing novel kidney markers, rather than using the traditional markers of kidney function, provides a major advantage, as they provide an opportunity to assess therapeutic interventions in real-time, as opposed to kidney function markers, which are slow to change. Oxidative damage is a contributing factor to progression. This study evaluates the effect of antioxidant treatment on active damage and CKD progression. Dogs with stable CKD will be enrolled and oxidative stress markers will be measured before, during, and after antioxidants supplementation. Investigators anticipate a reduction in oxidative-stress potentially reducing ongoing kidney damage and slowing down the progression rate of CKD.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.